Effect estimate: 24% reduction
Absolute Event Rate: 3.7% vs 4.8%
Number Needed to Treat: 91
Supports legacy effects of low-dose rosuvastatin in primary prevention; leaves open confirmation in prospective trials before practice change.
TEST 02 - Elsevier's Scopus, the largest abstract and citation database of peer-reviewed literature. Search and access research from the science, technology, medicine, social sciences and arts and humanities fields.
No takes yet. Share an insight, caveat, or question.
Boersma et al. (2021) conducted an editorial in Without clinically established cardiovascular disease (n=12,705). Rosuvastatin vs. Placebo was evaluated on Major adverse cardiac events (MACE), including CV death, myocardial infarction, and stroke (24% reduction).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: